Evidence map›Paper›PMID 37285096›Full record

ArticleAnnals of surgical oncology2023

Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer.

Harufumi Maki, Reed I Ayabe, Yujiro Nishioka, Tsuyoshi Konishi, Timothy E Newhook, Hop S Tran Cao, Yun Shin Chun, Ching-Wei D Tzeng, Y Nancy You, Jean-Nicolas Vauthey

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Reproducibility and efficiency of liver volumetry using manual method and liver analysis software.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2024
    Article
  9. Review
  10. Review
  11. Clinical efficacy of precision liver resection for primary liver cancer.American journal of translational research · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Harufumi MakiDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Reed I AyabeDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yujiro NishiokaDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tsuyoshi KonishiDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Timothy E NewhookDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hop S Tran CaoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yun Shin ChunDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ching-Wei D TzengDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Y Nancy YouDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jean-Nicolas VautheyDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. jvauthey@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS CA016672NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundFor patients with synchronous liver metastases (LM) from rectal cancer, a consensus on surgical sequencing is lacking. We compared outcomes between the reverse (hepatectomy first), classic (primary tumor resection first), and combined (simultaneous hepatectomy and primary tumor resection) approaches.

methodsA prospectively maintained database was queried for patients with rectal cancer LM diagnosed before primary tumor resection who underwent hepatectomy for LM from January 2004 to April 2021. Clinicopathological factors and survival were compared between the three approaches.

resultsAmong 274 patients, 141 (51%) underwent the reverse approach; 73 (27%), the classic approach; and 60 (22%), the combined approach. Higher carcinoembryonic antigen level at LM diagnosis and higher number of LM were associated with the reverse approach. Combined approach patients had smaller tumors and underwent less complex hepatectomies. More than eight cycles of pre-hepatectomy chemotherapy and maximum diameter of LM > 5 cm were independently associated with worse overall survival (OS) (p = 0.002 and 0.027, respectively). Although 35% of reverse-approach patients did not undergo primary tumor resection, OS did not differ between groups. Additionally, 82% of incomplete reverse-approach patients ultimately did not require diversion during follow-up. RAS/TP53 co-mutation was independently associated with lack of primary resection with the reverse approach (odds ratio: 0.16, 95% CI 0.038-0.64, p = 0.010).

conclusionsThe reverse approach results in survival similar to that of combined and classic approaches and may obviate primary rectal tumor resections and diversions. RAS/TP53 co-mutation is associated with a lower rate of completion of the reverse approach.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsRectal NeoplasmsHepatectomyHumansRectumRetrospective StudiesLiver resectionRectal cancerSomatic gene alterationSynchronous liver metastasis

Identifiers

PMID37285096
PMCPMC11816992
OpenAlexW4379601071

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.